mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA, Abeledo-Machado A, Perez PA, Faraoni EY, De Fino F, Rulli SB, Ferraris J, Pisera D, Gutierrez S, Thomas P, Díaz-Torga G.
Camilletti MA, et al.
Endocr Relat Cancer. 2019 May;26(5):497-510. doi: 10.1530/ERC-18-0409.
Endocr Relat Cancer. 2019.
PMID: 30856609